Difluprednate

In today's world, Difluprednate has gained great relevance in various aspects of daily life. Both on a personal and professional level, the presence of Difluprednate has become a determining factor that shapes our decisions, opinions and behaviors. With the advancement of technology and globalization, Difluprednate has managed to transcend borders and cultural barriers, becoming a topic of general interest and a meeting point for modern society. From its impact on the economy to its influence on politics and culture, Difluprednate has woven a network of connections that affects all corners of the planet. In this article, we will closely explore the fundamental role that Difluprednate plays in our daily lives and how it has managed to establish itself as a key element in the evolution of today's society.

Difluprednate
Clinical data
Trade namesDurezol
AHFS/Drugs.comMonograph
MedlinePlusa609025
License data
Routes of
administration		Eye drops
ATC code
Legal status
Legal status
Identifiers
  • phenanthren-17-yl] butanoate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.041.636 Edit this at Wikidata
Chemical and physical data
FormulaC27H34F2O7
Molar mass508.559 g·mol−1
3D model (JSmol)
  • 12CC(OC(=O)CCC)(C(=O)COC(C)=O)1(C)C(O)1(F)2()C(F)C2=CC(=O)C=C12C
  • InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27-/m0/s1
  • Key:WYQPLTPSGFELIB-JTQPXKBDSA-N
 ☒NcheckY (what is this?)  (verify)

Difluprednate, sold under the brand name Durezol, is a corticosteroid used for the treatment of post-operative ocular inflammation and pain.

It was approved for medical use in the United States in June 2008. It is available as a generic medication.

Medical uses

Difluprednate is indicated for the treatment of inflammation and pain associated with ocular surgery; and the treatment of endogenous anterior uveitis.

Clinical trials

Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a phase 3 study evaluating difluprednate for the treatment of anterior uveitis

References

  1. ^ a b c d "Durezol emulsion". DailyMed. 11 July 2022. Retrieved 7 March 2023.
  2. ^ "Drug Approval Package: Durezol (Difluprednate) NDA #022212". U.S. Food and Drug Administration (FDA). 25 July 2008. Retrieved 7 March 2023.
  3. ^ "Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain" (Press release). Sirion Therapeutics, Inc. 2008-06-24. Retrieved 2008-06-30.
  4. ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  5. ^ Clinical trial number NCT00501579 for "Study of Difluprednate in the Treatment of Uveitis" at ClinicalTrials.gov
  6. ^ Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS (May 2014). "Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study". Investigative Ophthalmology & Visual Science. 55 (5): 2993–3002. doi:10.1167/iovs.13-12660. PMC 4581692. PMID 24677110.


Stub icon

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia